Bicycle Therapeutics announces the appointment of Roger Dansey, M.D., and Hervé Hoppenot to its Board of Directors.
The new members bring extensive drug development and commercialization expertise to the company.
The appointments signal progress and anticipation of upcoming milestones in the pipeline.
Roger Dansey, M.D.
Brings experience from Pfizer, Seagen, and other pharmaceutical companies, with a significant role in developing important cancer therapies.
Hervé Hoppenot
Brings expertise from Incyte, Novartis Oncology, and Rhône Poulenc/Aventis, contributing to the growth and international presence of companies.
- The addition of Roger Dansey, M.D., and Hervé Hoppenot strengthens Bicycle Therapeutics' strategic direction and oncology expertise on the Board of Directors.
- Their backgrounds in drug development and commercialization align with the company's focus on next-generation targeted therapies for improved patient outcomes.
With the new appointments, Bicycle Therapeutics demonstrates a commitment to advancing its pipeline and delivering innovative therapies for underserved diseases.